Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.540
+0.140 (3.18%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.3 billion as of March 24, 2026. Its market cap has increased by 263.54% in one year.
Market Cap
1.30B
Enterprise Value
1.05B
1-Year Change
263.54%
Ranking
Category
Stock Price
$4.54
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.30B, an increase of 88.90%. That is a compound annual growth rate of 12.27%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 23, 2026 | 1.30B | -13.53% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Damora Therapeutics | 1.39B |
| Palvella Therapeutics | 1.39B |
| Trevi Therapeutics | 1.38B |
| MBX Biosciences | 1.34B |
| Rapport Therapeutics | 1.33B |
| Biohaven | 1.31B |
| Ardelyx | 1.30B |
| Immatics | 1.28B |